(EMAILWIRE.COM, March 13, 2019 ) 3D bioprinting market over the forecast period of 2016 to 2021. This market is expected to reach USD 1,332.6 Million by 2021, at CAGR of 26.5% from 2016 to 2021.

Key factors such as rising demand for organ transplantation, growing R&D in 3D bioprinting, increasing public and private investments in research, and rising use of 3D bioprinting in drug discovery are driving the growth of this market. However, the limitations of biomaterial-based products, lack of complete automation in 3D bioprinting, and socio-ethical concerns related to the use of 3D bioprinted products are the major challenges in this market.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170201787

3D Bioprinting Market : Target Audience
-3D Bioprinter manufacturers, suppliers, and distributors
-Pharmaceutical & biotechnology companies
-Cosmetic product manufacturers, suppliers, and distributors
-Healthcare institutions
-Clinical diagnostic centers
-Medical research laboratories
-Academic medical centers and universities
-Business research and consulting firms

North America is expected to command the largest share of the 3D bioprinting market in 2016, owing to increasing government initiatives, rising demand for organ transplants, and rising awareness due to conferences and trade shows. Europe is estimated to account for the second-largest share of the market in 2016. The increasing number of 3D bioprinting-related conferences, large number of research activities, and increasing application of 3D bioprinting in the cosmetic industry are some key factors driving the growth of the European market.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=170201787

The Asia-Pacific market is expected to grow at the highest CAGR from 2016 to 2021. The key factors influencing the growth of the Asia-Pacific market are the increase in overall and stem cell research activity, growing demand for organ transplantation, and rising initiatives by market players.

Organovo Holdings Inc. (U.S.), EnvisionTEC GmbH (Germany), Nano3D Biosciences, Inc. (U.S.), Cyfuse Biomedical K.K. (Japan), BioBots (U.S.), Aspect Biosystems Ltd. (Canada), 3Dynamic Systems Ltd. (U.K.), regenHU Ltd (Switzerland), Cellink (Sweden), Regenovo Biotechnology Co., Ltd. (China), Poietis (France), and GeSiM (Germany) are some of the key players operating in the global market.